Carl Zeiss Meditec AG (AFX) - Net Assets

Latest as of September 2025: €2.13 Billion EUR ≈ $2.49 Billion USD

Based on the latest financial reports, Carl Zeiss Meditec AG (AFX) has net assets worth €2.13 Billion EUR (≈ $2.49 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.40 Billion ≈ $3.98 Billion USD) and total liabilities (€1.28 Billion ≈ $1.49 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Carl Zeiss Meditec AG liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets €2.13 Billion
% of Total Assets 62.52%
Annual Growth Rate 9.89%
5-Year Change 26.85%
10-Year Change 149.98%
Growth Volatility 12.91

Carl Zeiss Meditec AG - Net Assets Trend (2014–2025)

This chart illustrates how Carl Zeiss Meditec AG's net assets have evolved over time, based on quarterly financial data. Also explore AFX total assets for the complete picture of this company's asset base.

Annual Net Assets for Carl Zeiss Meditec AG (2014–2025)

The table below shows the annual net assets of Carl Zeiss Meditec AG from 2014 to 2025. For live valuation and market cap data, see AFX stock market capitalisation.

Year Net Assets Change
2025-09-30 €2.13 Billion
≈ $2.49 Billion		 +3.46%
2024-09-30 €2.06 Billion
≈ $2.40 Billion		 -5.36%
2023-09-30 €2.17 Billion
≈ $2.54 Billion		 +7.03%
2022-09-30 €2.03 Billion
≈ $2.37 Billion		 +21.03%
2021-09-30 €1.68 Billion
≈ $1.96 Billion		 +15.64%
2020-09-30 €1.45 Billion
≈ $1.70 Billion		 +2.37%
2019-09-30 €1.42 Billion
≈ $1.66 Billion		 +7.78%
2018-09-30 €1.31 Billion
≈ $1.54 Billion		 +5.87%
2017-09-30 €1.24 Billion
≈ $1.45 Billion		 +45.89%
2016-09-30 €851.16 Million
≈ $995.10 Million		 +6.74%
2015-09-30 €797.45 Million
≈ $932.30 Million		 +5.73%
2014-09-30 €754.23 Million
≈ $881.77 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Carl Zeiss Meditec AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 336.2% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (September 2025)

Component Amount Percentage
Retained Earnings €1.58 Billion 74.42%
Other Components €541.39 Million 25.58%
Total Equity €2.12 Billion 100.00%

Carl Zeiss Meditec AG Competitors by Market Cap

The table below lists competitors of Carl Zeiss Meditec AG ranked by their market capitalization.

Company Market Cap
Alupar Investimento SA
SA:ALUP11
 $2.23 Billion
Kaiser Aluminum Corporation
NASDAQ:KALU
 $2.23 Billion
Curaleaf Holdings Inc.
TO:CURA
 $2.23 Billion
TMC the metals company Inc
NASDAQ:TMC
 $2.23 Billion
BW LPG Limited
NYSE:BWLP
 $2.23 Billion
Arena Star Group Ltd
TA:ARNA
 $2.23 Billion
MeHow Innovative Ltd. A
SHE:301363
 $2.23 Billion
Mayora Indah Tbk
JK:MYOR
 $2.23 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Carl Zeiss Meditec AG's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 2,041,697,000 to 2,116,506,000, a change of 74,809,000 (3.7%).
  • Net income of 141,210,000 contributed positively to equity growth.
  • Dividend payments of 52,522,000 reduced retained earnings.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income €141.21 Million +6.67%
Dividends Paid €52.52 Million -2.48%
Other Changes €-13.88 Million -0.66%
Total Change €- 3.66%

Book Value vs Market Value Analysis

This analysis compares Carl Zeiss Meditec AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.09x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 1.93x to 1.09x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-09-30 €13.59 €26.26 x
2018-09-30 €14.46 €26.26 x
2019-09-30 €15.64 €26.26 x
2020-09-30 €16.01 €26.26 x
2021-09-30 €18.55 €26.26 x
2022-09-30 €22.53 €26.26 x
2023-09-30 €24.14 €26.26 x
2024-09-30 €23.32 €26.26 x
2025-09-30 €24.18 €26.26 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Carl Zeiss Meditec AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 6.67%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 6.34%
  • • Asset Turnover: 0.65x
  • • Equity Multiplier: 1.61x
  • Recent ROE (6.67%) is below the historical average (10.80%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2014 10.48% 8.24% 0.88x 1.45x €3.43 Million
2015 8.26% 5.99% 0.91x 1.51x €-13.09 Million
2016 12.32% 9.03% 0.87x 1.56x €18.55 Million
2017 11.06% 11.30% 0.73x 1.34x €12.91 Million
2018 9.78% 9.87% 0.77x 1.28x €-2.88 Million
2019 11.42% 10.95% 0.72x 1.45x €19.91 Million
2020 8.55% 9.16% 0.66x 1.41x €-20.79 Million
2021 14.24% 14.35% 0.69x 1.44x €70.34 Million
2022 14.59% 15.45% 0.67x 1.40x €92.40 Million
2023 13.45% 13.90% 0.69x 1.40x €74.45 Million
2024 8.75% 8.65% 0.61x 1.66x €-25.44 Million
2025 6.67% 6.34% 0.65x 1.61x €-70.44 Million

Industry Comparison

This section compares Carl Zeiss Meditec AG's net assets metrics with peer companies in the Medical Instruments & Supplies industry.

Industry Context

  • Industry: Medical Instruments & Supplies
  • Average net assets among peers: $6,157,328,554
  • Average return on equity (ROE) among peers: -96.86%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Carl Zeiss Meditec AG (AFX) €2.13 Billion 10.48% 0.60x $2.23 Billion
SCHOTT Pharma AG & Co. KGaA (1SXP) $709.04 Million 17.68% 0.69x $2.39 Billion
RENAU.UNSP.ARD 1/5 EO-20 (56S0) $2.51 Billion 34.85% 1.01x $16.46 Billion
MEDIMI AB AK (79T) $332.69K -959.52% 4.12x $427.04K
TEVANO SYSTEMS HLDGS INC. (7RBA) $-1.31 Million 0.00% 0.00x $210.67K
STEVANATO GROUP SPA O.N. (87N) $841.66 Million 15.96% 0.69x $831.06 Million
CARL ZEISS MEDITEC ADR 1 (AFXA) $2.06 Billion 8.69% 0.65x $2.14 Billion
Bio-gate AG (BIG1) $1.55 Million -51.89% 1.13x $5.32 Million
COLOPLAST SP.ADR 1/10 DK1 (CBH) $8.29 Billion 56.75% 3.52x $12.73 Billion
ESSILORLUXOTTICA 1/2/O.N. (ESLC) $41.00 Billion 5.75% 0.57x $93.24 Billion

About Carl Zeiss Meditec AG

F:AFX Germany Medical Instruments & Supplies
Market Cap
$2.69 Billion
€2.30 Billion EUR
Market Cap Rank
#5870 Global
#894 in Germany
Share Price
€26.26
Change (1 day)
+1.39%
52-Week Range
€23.34 - €65.90
All Time High
€196.24
Categories
Companies in Germany Medical Instruments & Supplies
About

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for ret… Read more